Abstract
Undifferentiated autoinflammatory diseases (uAIDs) constitute a group of rare autoinflammatory diseases that do not correspond in their phenotype and genotype to known monogenic AIDs. They often manifest as juvenile arthritis, particularly its systemic variant. A comprehensive understanding of the clinical, laboratory, and genetic characteristics of undifferentiated AIDs is essential for timely diagnosis and the initiation of targeted therapy. This approach can reduce the risk of complications, disability, and improve prognosis. Objective. To identify the peculiarities of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation. Patients and methods. We performed a comparative retrospective analysis of clinical and laboratory manifestations of disease in 52 patients with febrile syndrome hospitalised in the rheumatology department of the National Medical Research Centre for Child Health between 1 March 2013 and 31 August 2022, with a referral diagnosis of juvenile idiopathic arthritis (JIA): 26 (50%) patients each with and without variants in genes associated with autoinflammation. Results. Due to the presence of febrile syndrome, molecular genetic study was performed in all patients. No variants in genes associated with known monogenic AID were detected in any patient. In 26 patients, 36 variants in genes associated with autoinflammation were identified, including: 1 (2.8%) variant classified as pathogenic in the TREX1 gene (c.914A>G, p.Y305C), 1 (2.8%) probably pathogenic variant in the NFAT5 gene (c.74-1 G>C), 4 (11.1%) were probably benign variants in STAT2, IL23R, TNFRSF1B and PSMB8 genes, 30 (83.3%) were variants of uncertain significance in IL10 genes, NLRP12, LPIN2, NLRC4, PSMB8, PRF1, CARD14, IFIH1, LYST, COPA, PLCG2, STXBP2, LACC1, PTHR1, STAT4, TNFAIP3, SLC7A7, all in heterozygous state. Patients with variants in genes associated with autoinflammation and a disease phenotype corresponding to uAID (n = 26) were verified as having uAID, while patients without variants in genes and a disease phenotype not corresponding to AID were confirmed as having systemic JIA (sJIA). At disease debut, fever was recorded in all patients, rash and joint involvement in 51 (98%) and 46 (88.5%) patients in the total cohort: of these, 26 (100%) and 25 (96.1%); 24 (92.3%) and 22 (84.7%) patients with uAIDs and sJIA, respectively. Similar symptoms in patients with uAIDs and sJIA were characterised by the following features: in sJIA, the fever was continuous and the rash was patchy-papular; in uAIDs, the fever lasted <7 days and the rash was predominantly erythematous, urticarial, small-spotted, large-spotted and mixed. Patients with uAIDs had clinical manifestations that were absent in patients diagnosed with sJIA: attack-like fever (100%), erythematous (15.3%), erythematous (15.3%), urticarial (11.5%), mixed rash (3.8%), eye lesions (conjunctivitis and congenital cataract) (11.5%), hydrocephalus (3.8%), combination of hydrocephalus and psycho-verbal retardation (3.8%), combination of headache and psycho-verbal retardation (3.8%), hearing loss (3.8%). Conclusion. The presence of variants in genes associated with autoinflammation can manifest a wide variety of clinical symptoms, therefore, it is advisable to perform molecular genetic studies to detect variants in genes in all patients with suspected sJIA, fever, joint involvement in combination with rash, eye inflammation, central nervous system involvement and/or other manifestations, associated with AID/autoinflammation to confirm/exclude the diagnosis of known monogenic or multifactorial AID at an early stage, timely verification of the diagnosis of uAID, initiation of pathogenetic therapy and prevention of complications. Key words: autoinflammatory syndrome, undifferentiated autoinflammatory diseases, undifferentiated recurrent fever syndrome, molecular genetic diagnosis, rheumatology, paediatrics, children